株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

口腔粘膜炎 : パイプライン製品の分析

Oral Mucositis - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 192750
出版日 ページ情報 英文 96 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.88円で換算しております。
Back to Top
口腔粘膜炎 : パイプライン製品の分析 Oral Mucositis - Pipeline Review, H1 2018
出版日: 2018年02月20日 ページ情報: 英文 96 Pages
概要

口腔粘膜炎は最も一般的な粘膜炎の一種で、がんの外科手術・化学療法・放射線治療の際に併発する衰弱性疾患です。主な症状として、口腔内部の色調異常や唾液分泌減退、粘膜構造の変化、唇・舌での浮腫の発生などがあります。主な治療法としては、口腔洗浄(マウスケア)や、口腔内部の創面切除(デブリードメント)などがあります。

当レポートでは、世界各国での口腔粘膜炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

口腔粘膜炎の概要

治療薬の開発

  • 口腔粘膜炎向けパイプライン製品:概要
  • 口腔粘膜炎向けパイプライン製品:比較分析

各企業で開発中の口腔粘膜炎治療薬

大学/研究機関で研究中の口腔粘膜炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

口腔粘膜炎治療薬:開発中の製品の一覧(企業別)

口腔粘膜炎治療薬:研究中の製品の一覧(大学/研究機関別)

口腔粘膜炎治療薬の開発に従事している企業

  • Aldeyra Therapeutics, Inc.
  • Cellceutix Corporation
  • Colby Pharmaceutical Company
  • Daewoong Pharmaceutical Co., Ltd.
  • Galera Therapeutics, Inc.
  • Onxeo SA
  • Oragenics, Inc.
  • 大塚ホールディングス
  • Soligenix, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Spherium Biomed S.L.

口腔粘膜炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

口腔粘膜炎治療薬:開発が休止状態の製品

口腔粘膜炎治療薬:開発が中止された製品

口腔粘膜炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

目次
Product Code: GMDHC10162IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2018, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Oral Mucositis - Overview
    • Oral Mucositis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Oral Mucositis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Oral Mucositis - Companies Involved in Therapeutics Development
    • Clevexel Pharma SAS
    • Colby Pharmaceutical Co
    • Galera Therapeutics Inc
    • Humanetics Corp
    • Innovation Pharmaceuticals Inc
    • Monopar Therapeutics LLC
    • Oragenics Inc
    • Soligenix Inc
    • Spectrum Pharmaceuticals Inc
    • Spherium Biomed SL
  • Oral Mucositis - Drug Profiles
    • AG-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avasopasem manganese - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCD-600 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clonidine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVXL-0095 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Oral Mucositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate SOD2 for Oral Mucositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HYLP-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melatonin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • phenylbutyrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pralatrexate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize KGFR for Chemotherapy Induced Gastrointestinal Mucositis and Oral Mucositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Oral Mucositis - Dormant Projects
  • Oral Mucositis - Discontinued Products
  • Oral Mucositis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 29, 2018: Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications - Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases
      • Jan 16, 2018: Innovation Pharmaceuticals Presents at 2018 Biotech Conference; Oral Mucositis Drug Candidate Garners Exceptional Interest After Successful Phase 2 Trial
      • Jan 04, 2018: Data from Galera Therapeutics' 223-Patient Phase 2b Clinical Trial of GC4419 to be Presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium
      • Jan 03, 2018: Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM)
      • Jan 02, 2018: Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis
      • Dec 18, 2017: Galera Therapeutics Reports Statistically Significant Results in a 223-Patient Phase 2b Trial of GC4419 for Severe Oral Mucositis in Patients with Head and Neck Cancer
      • Dec 18, 2017: Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value
      • Dec 12, 2017: Innovation Pharmaceuticals Granted European Patent for Brilacidin in the Prevention of Oral Mucositis
      • Dec 11, 2017: Innovation Pharmaceuticals Reports Positive Topline Results from Phase II Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients
      • Nov 16, 2017: Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients
      • Nov 09, 2017: Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 2nd Annual Superbugs & Superdrugs USA Conference
      • Oct 26, 2017: Innovation Pharmaceuticals Aims to Develop First Drug for Approval in Prevention of Oral Mucositis in Head and Neck Cancer Patients as Phase 2 Clinical Trial of Brilacidin Completes
      • Oct 24, 2017: Broad-Spectrum Innate Defense Regulator Platform Technology to be Presented at the Peptide Therapeutics Foundation Symposium
      • Oct 18, 2017: Innovation Pharmaceuticals to Complete Phase 2 Trial of Brilacidin for Oral Mucositis in Cancer Patients
      • Oct 05, 2017: Dusquetide Technology Platform to be Presented at the 2nd World Congress and Expo on Immunology
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Oral Mucositis, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Oral Mucositis - Pipeline by Clevexel Pharma SAS, H1 2018
  • Oral Mucositis - Pipeline by Colby Pharmaceutical Co, H1 2018
  • Oral Mucositis - Pipeline by Galera Therapeutics Inc, H1 2018
  • Oral Mucositis - Pipeline by Humanetics Corp, H1 2018
  • Oral Mucositis - Pipeline by Innovation Pharmaceuticals Inc, H1 2018
  • Oral Mucositis - Pipeline by Monopar Therapeutics LLC, H1 2018
  • Oral Mucositis - Pipeline by Oragenics Inc, H1 2018
  • Oral Mucositis - Pipeline by Soligenix Inc, H1 2018
  • Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2018
  • Oral Mucositis - Pipeline by Spherium Biomed SL, H1 2018
  • Oral Mucositis - Dormant Projects, H1 2018
  • Oral Mucositis - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Oral Mucositis - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Oral Mucositis, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top